CN Mobile Logo


Kidney Cancer

Kidney Cancer

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

Cabozantinib significantly improved the overall survival of patients with previously treated advanced RCC, according to the second interim analysis of the METEOR trial.

Despite improved understanding of the molecular features of renal tumors, increasing expertise in surgical management of localized renal cancers, and multiple effective systemic therapies for metastatic cancer, mortality from renal cell carcinoma remains largely unchanged.

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.


Subscribe to Kidney Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.